Trial
NCT00489216
Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
Genentech, Inc.
Condition
Graft Versus Host Disease
Intervention
efalizumab
Why stopped
insufficient accrual/funding withdrawn
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-23